Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study.

Ruggiero AngeloGabriella FabbrocicniSara CacciapuotiLuca PotestioLucia GalloMatteo Megna

Published in: Clinical, cosmetic and investigational dermatology (2023)

Our data confirm tildrakizumab as an effective and generally safe treatment for the management of moderate-to-severe psoriasis, with high rates of both PASI90 and PASI100 responses, and very few reported adverse events, up to 52 weeks of follow-up.

Keyphrases

high intensity
electronic health record
machine learning
big data
artificial intelligence